Airway epithelial-targeted nanoparticles for asthma therapy

Area of Science:

• Pulmonary Medicine
• Nanotechnology
• Drug Delivery

Background:

• Asthma is a chronic airway inflammatory disease characterized by airflow obstruction and hyperresponsiveness.
• Current treatments often fail to achieve adequate control, leaving patients susceptible to exacerbations, frequently triggered by viral infections.
• Airway epithelial cell dysfunction is a key driver of asthma pathology, necessitating targeted therapeutic approaches.

Purpose of the Study:

• To review current advancements in nanoparticle (NP)-mediated drug delivery to the airway epithelium for asthma therapy.
• To highlight the potential of NPs, including extracellular vesicles (EVs) and synthetic variants, in addressing epithelial dysfunction in asthma.
• To discuss future perspectives and challenges in developing NP-based asthma treatments.

Main Methods:

• Review of existing literature on nanoparticle applications in respiratory diseases, specifically asthma.
• Analysis of NP properties, including EVs and synthetic NPs, for targeting airway epithelial cells.
• Discussion of strategies to overcome biological barriers like mucus and immune responses.

Main Results:

• Nanoparticles offer a promising strategy for delivering therapeutics to airway epithelial cells in asthma.
• EVs exhibit natural targeting and low immunogenicity, while synthetic NPs can be engineered for enhanced targeting and barrier penetration.
• Targeting epithelial cells with NPs can potentially repair dysfunction, improve barrier integrity, and modulate immune responses.

Conclusions:

• Nanoparticle-mediated drug delivery to the airway epithelium represents a significant therapeutic avenue for improved asthma control.
• Further development of novel NP formulations and preclinical models is crucial for advancing this strategy.
• Targeting airway epithelium with NPs holds potential for novel asthma therapies and exacerbation prevention.